We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo
  Request new password

Andrew Serafini Fenwick & West LLP

Andrew Serafini

Results 1 to 1 of 1



IP provisions and ROI for state-funded stem cell-based products and technologies in California *

USA - May 31 2012
The California Institute of Regenerative Medicine (CIRM) reaches the end of its initial charter in 2017 and recently published its Transition Plan.

Co-authors: Gene Yee.